These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 18192922

  • 1. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
    Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, Ursi M, Verrienti R, Maiorano A, Zaza G, Ranieri E, Gesualdo L, Ditonno P, Bettocchi C, Schena FP, Grandaliano G.
    Transplantation; 2008 Jan 15; 85(1):125-34. PubMed ID: 18192922
    [Abstract] [Full Text] [Related]

  • 2. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma.
    Revelo MP, Federspiel C, Helderman H, Fogo AB.
    Nephrol Dial Transplant; 2005 Dec 15; 20(12):2812-9. PubMed ID: 16221712
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
    Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, Gesualdo L, Schena FP, Grandaliano G.
    J Am Soc Nephrol; 2005 Dec 15; 16(12):3755-62. PubMed ID: 16236802
    [Abstract] [Full Text] [Related]

  • 4. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK, Weir MR.
    Curr Opin Organ Transplant; 2008 Dec 15; 13(6):614-21. PubMed ID: 19060552
    [Abstract] [Full Text] [Related]

  • 5. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 6. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M.
    Transplantation; 2006 Aug 27; 82(4):550-7. PubMed ID: 16926600
    [Abstract] [Full Text] [Related]

  • 7. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin.
    Loverre A, Ditonno P, Crovace A, Gesualdo L, Ranieri E, Pontrelli P, Stallone G, Infante B, Schena A, Di Paolo S, Capobianco C, Ursi M, Palazzo S, Battaglia M, Selvaggi FP, Schena FP, Grandaliano G.
    J Am Soc Nephrol; 2004 Oct 27; 15(10):2675-86. PubMed ID: 15466272
    [Abstract] [Full Text] [Related]

  • 8. Rapamycin attenuates the severity of murine adriamycin nephropathy.
    Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM.
    Am J Nephrol; 2009 Oct 27; 29(4):342-52. PubMed ID: 18948688
    [Abstract] [Full Text] [Related]

  • 9. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W.
    J Am Soc Nephrol; 2005 Jul 27; 16(7):2063-72. PubMed ID: 15917339
    [Abstract] [Full Text] [Related]

  • 10. The effect of combined rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats, compared with cyclosporine or rapamycin in isolation.
    Murphy GJ, Bicknell GR, Nicholson ML.
    Transpl Int; 2003 May 27; 16(5):347-53. PubMed ID: 12759727
    [Abstract] [Full Text] [Related]

  • 11. The influence of tubular phenotypic changes on the development of diffuse interstitial fibrosis in renal allografts.
    Özdemir BH, Özdemir AA, Colak T, Sezer S, Haberal M.
    Transplant Proc; 2011 Mar 27; 43(2):527-9. PubMed ID: 21440751
    [Abstract] [Full Text] [Related]

  • 12. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.
    Yilmaz M, Nart A, Sen S, Tasli F, Uslu A, Hur E, Ozkahya M, Hoscoskun C, Toz H.
    Nephrology (Carlton); 2010 Sep 27; 15(6):653-8. PubMed ID: 20883287
    [Abstract] [Full Text] [Related]

  • 13. Molecular mechanisms of renal allograft fibrosis.
    Waller JR, Nicholson ML.
    Br J Surg; 2001 Nov 27; 88(11):1429-41. PubMed ID: 11683737
    [Abstract] [Full Text] [Related]

  • 14. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 27; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 16. [Effects of hypoxia and tumor necrosis factor-alpha on production of plasminogen activator inhibitor-1 in human proximal renal tubular cells].
    Torii K, Kimura H, Li X, Okada T, Imura T, Furusaki F, Ono T, Yoshida H.
    Rinsho Byori; 2005 Mar 27; 53(3):207-12. PubMed ID: 15839049
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical characterization of glomerular and tubulointerstitial infiltrates in renal transplant patients with chronic allograft dysfunction.
    Divella C, Rossini M, Loverre A, Schena A, Maiorano A, Gesualdo V, Zaza G, Grandaliano G, Schena FP.
    Nephrol Dial Transplant; 2010 Dec 27; 25(12):4071-7. PubMed ID: 20595199
    [Abstract] [Full Text] [Related]

  • 18. Progression of renal allograft histology after renal transplantation in recurrent and nonrecurrent immunoglobulin A nephropathy.
    Jeong HJ, Park SK, Cho YM, Kim MS, Kim YS, Choi J, Kim SI, Lim BJ.
    Hum Pathol; 2008 Oct 27; 39(10):1511-8. PubMed ID: 18620732
    [Abstract] [Full Text] [Related]

  • 19. Pathogenesis of tubulointerstitial fibrosis in chronic allograft dysfunction.
    Strutz F.
    Clin Transplant; 2009 Dec 27; 23 Suppl 21():26-32. PubMed ID: 19930313
    [Abstract] [Full Text] [Related]

  • 20. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli.
    Esposito C, Foschi A, Parrilla B, Cornacchia F, Fasoli G, Plati AR, De Mauri A, Mazzullo T, Scudellaro R, Dal Canton A.
    Transplant Proc; 2004 Apr 27; 36(3):695-7. PubMed ID: 15110634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.